Skip to main content
. 2019 Jun;60(7):2474–2480. doi: 10.1167/iovs.18-26452

Figure 1.

Figure 1

Expression of downstream targets in UM. (A) Western blot analysis of 17 primary UM and three nontumor choroids. Variations in pERK1/2 and pMEK1/2 levels were observed in tumors with GNAQ/11 mutations. Most tumors showed lower levels than normal choroidal samples suggesting a lower activation. Almost all GNAQ/11 mutant tumors showed higher levels of pAKT than normal choroidal samples suggesting activation of PI3K/AKT pathway in most UM. (B) Baseline pERK1/2, pMEK1/2 and pAKT levels in different UM cell lines and in ARPE-19 cells. GNAQ mutant cell lines (92.1, MEL202 and MEL270) showed variation in pERK1/2 and pMEK levels. (C) pERK1/2 levels in 39 primary UM by immunohistochemistry. A subset of UM with GNAQ/11 mutation show weak or no pERK1/2 immunostaining.